Here’s what Citi is saying about the CSL share price

Happy healthcare workers in a labs

Happy healthcare workers in a labs

The CSL Limited (ASX: CSL) share price has been a strong performer in recent weeks.

Since this time last month, the biotherapeutics company’s shares have risen over 8% to $299.00.

Can the CSL share price keep climbing?

The good news for investors is that it may not be too late to snap up CSL shares.

According to a note out of Citi, its analysts have retained their buy rating and $340.00 price target on its shares.

Based on the current CSL share price, this implies potential upside of almost 14% for investors over the next 12 months.

What did the broker say?

Citi was pleased, but not surprised, to learn that the US Food and Drugs Administration (FDA) has approved CSL’s HEMGENIX (EtranaDez) gene therapy for haemophilia B.

The broker expects this to have a neutral impact on a short term basis due to the company already being the market leader for haemophilia treatments. However, it does cement CSL’s position in the market, which is good news for the long term. Citi commented:

As expected, CSL received FDA approval for its gene therapy for haemophilia B, HEMGENIX (EtranaDez), the first and only one-time gene therapy approved for haemophilia B.

Whilst an exciting new treatment option for patients, we expect HEMGENIX to be neutral on an NPV basis for CSL given 1) the cannibalization of Idelvion sales (~$650m/~6% of CSL total sales): CSL Idelvion is the current standard of care in haemophilia B with ~47% market share across key markets, and 2) in a defensive move, the therapy was licensed from uniQure in 2021 at a cost of ~US$750m (acquisition+pre-launch costs) + royalties and milestones.

CSL plans to launch HEMGENIX in the US & EU in Q1’23, but it will be a slow and gradual process as the payment models are yet to be finalized (likely to be upfront, with variations in payment models in the EU). Maintain Buy, $340 TP.

Elsewhere, Macquarie responded to the news by retaining its outperform rating and lifting its price target by 4.1% to $343.00. The broker expects the therapy to have a positive impact on its earnings over the long term and has boosted its valuation to reflect this.

The post Here’s what Citi is saying about the CSL share price appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of November 1 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor James Mickleboro has positions in CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/WTLuUOH

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s